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Objective. To determine the fatal and non-fatal cardiovascular event rate in patients with intermittent claudication treated
with antiplatelet agents.
Methods and design. Patients with PAD-II stage Fontaine (n ¼ 223) and sex and age matched controls (n ¼ 446) were
followed up from 1974 to 1998. All patients were treated with antiplatelet agents (aspirin, 325 mg once daily or ticlopidine,
250 mg twice daily) and for risk factors, if present. The end points were death for any cause (vascular event, cancer, and
others) and non-fatal vascular events (myocardial infarction, ischemic/hemorrhagic stroke, and leg amputation).
Results. PAD patients had a significantly higher mortality rate than controls (3.99 vs. 2.53 deaths for 100 patients per year,
respectively), cancer (mostly lung, stomach and colon) and vascular mortality accounted for such difference. The incidence of
non-fatal vascular events was three times higher in patients than in controls (1.7 vs. 0.56, 100 patients per year, respectively,
p , 0.05) even considering amputation separately (0.28 vs. 0.00, 100 patients per year, p , 0.05). No difference between
patients treated with aspirin or ticlopidine could be found in both end points.
Conclusions. Vascular mortality and morbidity, despite the use of antiplatelet agents, are still higher than sex and age
matched controls; however, the commonest cause of death is cancer.
Introduction
Peripheral arterial disease (PAD) at the second stage
Fontaine (Intermittent Claudication) affects 1–5% of
population in the age range from 40 to 80.1 It is
characterized by a relatively benign local evolution,
only a minority of patients undergo an amputation,
while life expectancy of patients with PAD is negative
because of the high incidence of coronary or cerebro-
vascular events.2,3 Among patients presenting to the
physician for intermittent claudication 30% will be
dead, 20% will experience a non-fatal vascular event,
and 2% will require a major amputation of the lower
limbs within 5 years. Such history, which dates back at
least 20 years ago, would predict that only one out of
ten patients with intermittent claudication would be
alive after 15 years from diagnosis. Since cardiovas-
cular mortality of western population has decreased in
the last decades,4 – 6 there is, indeed, little doubt that
improved management of risk factors for atherosclero-
sis and antiplatelet therapy have changed the natural
history of PAD, however, an updated picture is not
available so far. Data about such new natural history
are critical for two reasons: the first one consists in
knowing at which extent randomized clinical trials
and recommendations on management affect natural
history of PAD, the second one consists in the fact that
a precise actual estimate of the incidence of events is
fundamental for planning and designing future
clinical trials.
The aim of this study was to assess the causes of
death and the incidence of non-fatal vascular events in
a cohort of PAD patients with claudicatio intermittens
living in the North of Italy and followed up from 1974
till 1998. Treatment of these patients encompassed
antiplatelet therapy with aspirin or ticlopidine, and
management of risk factors for cardiovascular disease7
(smoke, hypertension, diabetes, hypercholesterolemia,
and unfitness) with lifestyle changes and drugs.
Methods
We studied 223 patients intermittent claudication
referred to a primary vascular diagnostic center of
the University of Trieste (North East of Italy). The
diagnosis was made on the following basis: symptoms
of intermittent claudication (according to WHO
criteria: leg pain on walking disappearing in less
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than 10 min on standing), and ankle/brachial pressure
index less than 0.80 in either leg at rest (two
assessments on separate days).
After selection of each patient, two sex and age (^2
years) matched controls free from symptoms of PAD
were randomly selected, from the Regional Health
Service Data Base (RHSDB). RHSDB contains vital
status and health data independently from hospitaliz-
ation of all the legal residents living in the region.
Controls with the same family name of one of the
patients were excluded. All patients accepted to
participate in the study, if a control subject refused
(8% of all putative controls contacted) he or she has
been replaced within the time reported above. In total
446 matched controls (Control Group) living in the
same area was enrolled during the same time period.
Patients with PAD were regularly followed up on
every six months. Controls were examined only on
entry to obtain informed consent and assess risk
factors and previous vascular events. Patients were
asked to choose the antiplatelet therapy, aspirin
(325 mg once a day) or ticlopidine (250 mg twice a
day), after being informed of and based on their
different side effects. If a patient did not express any
preference, the antiplatelet therapy was randomly
assigned by the physician. A total of 131 patients were
treated with aspirin (ASA Group), and 92 with
ticlopidine (TCL Group). All patients were provided
a list of common aspirin-containing products and were
instructed to avoid them. Acetaminophen was sup-
plied as an alternative analgesic. A letter informing
about the purposes of the study and the results of the
clinical examination has been sent to the GP of patients
and controls. At each follow-up examination, risk
factors for cardiovascular diseases (cigarette smoking,
hypertension, diabetes, hypercholesterolemia) have
been re-evaluated and treated according to the
recommendations of good clinical practice in force at
that time. At the first examination hypertension was
diagnosed if blood arterial pressure was
$140/90 mm/Hg, diabetes (plus impaired glucose
tolerance) if the fasting plasma level was .110 mg/dl
or120 after oral glucose test, and hypercholesterolemia
if LDL cholesterol was above 160 mg/dl. The com-
pliance to antiplatelet therapy was assessed with
platelet aggregation test according to Born’s method
and, when necessary, reinforced with the patient. After
each examination, each patient’s GP was informed
about the last clinical and laboratory data (smoking
habits, blood lipid levels, blood pressure, glicemia,
eventually HbA1c) and about therapy or recommen-
dations provided to the patients. We did not influence
any therapeutic intervention in controls. During the
whole study, all drugs for the cardiovascular risk
factors (e.g. statins and other antihypertensive agents)
were accessible both to patients and to controls.
The study population was followed up for 24 years
to assess fatal and non-fatal events. Observation ended
either when a fatal event occurred, or on Dec 31st 1998.
Fatal events were divided into vascular, cancer, and
due to other causes. Deaths were classified as vascular
if due to myocardial infarction, ischemic/hemorrhagic
stroke, and ‘other vascular causes’. Deaths from ‘other
vascular causes’ were any death that was not clearly
non-vascular and did not meet the criteria for fatal
ischemic/hemorrhagic stroke or fatal myocardial
infarction. When it was not possible to establish any
cause of death, it was classified as unknown. Non-fatal
events considered were: myocardial infarction, ische-
mic/hemorrhagic stroke, and major (leg) amputation.
For both PAD patients and controls, the occurrence
of death and/or hospitalization was verified yearly by
checking the Regional Health Service Database and the
Hospital Database, respectively, for deaths and in-
hospital non-fatal events. From the Hospital Database
the number of hospitalizations and total days spent in
the hospital have been obtained for both patients and
controls.
The diagnosis of the cause of death was made on the
basis of necroscopy, of in-hospital clinical report or, if
no other source was available, on Regional Health
Service Database. The diagnosis of non-fatal event was
made on in-hospital clinical reports and based on the
following criteria: for myocardial infarction, elevation
of CK, CK-MB, LDH or AST 2 or more times the upper
limit of laboratory normal level and the development
of new Q waves in at least two adjacent ECG leads or
new dominant R wave in V1 (R $ 1 mm.S in V1); for
ischemic/hemorrhagic stroke, acute neurological vas-
cular event with focal signs after at least 24 h,
accompanied by appropriate CT report, after 1980.
Statistical analysis. The data of follow-up have been
reported as incidence of events per every 100
patients/year (100 patient-yr) of observation and
absolute numbers of events. Base-line data and end-
points of the study in the different categories have
been compared with the use of x2: Odds ratio (O.R.)
and 95% confidence intervals (C.I.) were also calcu-
lated. The Kaplan–Meier method, with log rank test,
was used to estimate overall survival functions.
Comparisons of hospitalizations data have been
compared with Mann–Whitney U test or x2 test,
when appropriate. The statistical analysis has been
carried out with Statistical Package for Social Sciences
(SPSS) version 11.0. A probability of less than 0.05 was
considered statistically significant.
For comparison purposes, the data of the Consen-
sus Document (3) have reported as number of events
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in a period of observation of 100 patients-yr, consistent
with our study, assuming that the number of
patients/year of the consensus is 425. This figure
was obtained subtracting to the theoretical total time
of exposure (100 patients *5 years, i.e. 500 patients/-
year) the missing years due to the deaths of the
patients (30 dead patients times 2.5 years, average time
of the death).
Results
Recruitment and examinations were carried out from
January 1974 till December 1992. Baseline character-
istics of the study population are reported in Table 1.
Patients with PAD are considered as a whole (PAD
Group) and as divided into patients receiving aspirin
(ASA Group) or ticlopidine (TCL Group).
Both groups of patients were followed till Dec 31st
1998; the median follow-up was 13 years for each
group, yielding a population of 2531 patients/year for
the PAD Group, and 5370 subjects/year for the Control
Group. The causes of death were determined by
autopsy in 46% of the PAD Group and in 52% of the
Control Group; in 4 subjects of the Control Group and
in 5 patients of the PAD Group the causes of death had
to be classified as unknown. None was lost at follow-
up.
Table 2 shows the incidence of fatal and non-fatal
events of the study population. The PAD Group
experienced significantly more fatal as well as non-
fatal events, as compared with Control Group.
Fatal events. In total, 101 PAD patients (3.99/100
patient-yr) and 136 patients control patients (2.53/100
patient-yr) had died (Table 2 and Fig. 1). Both vascular
and non-vascular deaths were more common in the
PAD Group than in the Control Group: the incidence
of all vascular deaths was 1.50 vs. 0.93, 100 patient-yr
ðp , 0:05Þ (Table 2 and Fig. 2), and the incidence of
non-vascular death was 2.49 vs. 1.60, 100 patient-yr
ðp , 0:05Þ: Among the causes of non-vascular deaths,
the incidence of cancer was significantly higher in the
PAD Group than in the Control Group (1.74 vs. 0.84,
100 patient-yr; p , 0:05) (Table 2 and Fig. 3). In
particular, a higher incidence of cancer of the lungs
(0.83 vs. 0.43, 100 patient-yr, p , 0:05) and of the
digestive tract (0.40 vs. 0.19, 100 patient-yr, p , 0:05)
was observed. The prevalence of other causes was not
different.
Non-fatal events. A major difference was noted also
in non-fatal events: 50 patients in the PAD Group
(1.98/100 patient-yr) vs 30 control patients (0.56/100
years).
Table 1. Baseline characteristics of the study population.
Control Group (446) PAD Group (223) ASA Group (131) TCL Group (92)
Age at diagnosis
Mean (range) 64 (39–85) 64 (40–83) 64 (40–83) 63 (45–82)
Men n (%) 360 (81) 180 (81) 112 (85) 68 (74)
Risk factors n (%)
Hypercholesterolemia 98 (22) 59 (26) 36 (27) 23 (25)
Hypertension 83 (19)* 102 (46) 60 (46) 42 (46)
Diabetes mellitus 52 (12)* 61 (27) 29 (22) 32 (35)
Smoking habits 124 (28)* 132 (59) 78 (59) 54 (59)
Previous vascular event n (%)
Myocardial infarction 31 (7)* 35 (16) 19 (15) 16 (17)
Stroke 9 (2)* 20 (9) 13 (10) 7 (8)
PAD Group, peripheral arterial occlusive disease group; ASA Group, patients treated with aspirin; TCL, patients treated with ticlopidine.
*Indicates the comparison between Control Group and PAD Group; p # 0:05.
Fig. 1. Kaplan–Meier curves for all-cause death in controls
(Control Group) and in patients with peripheral arterial
disease (PAD Group). On the axis of time are reported also
the number of subjects at risk at the beginning of each time
period. *Log rank test p # 0:05.
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ASA and TCL Groups. During the follow-up, no
adverse drug-related experiences was severe or
sufficient to result in permanent discontinuation of
study drugs, either in the ASA or TCL Groups, though
the study patients often reported minor drug-related
side effects. In the ASA Group, side effects were to
upper gastrointestinal discomfort (8) and minor
bleeding (1.5%). The similar figures in the TCL were
14 and 6%. The incidence of fatal events was similar in
both the ASA and TCL Group (Table 2). The incidence
of non-fatal events was slightly but significantly
higher in the TCL Group than in the ASA Group, the
incidence of myocardial infarction accounting for such
difference (1.54 vs. 1.14, 100 patient-yr; p # 0:05) (see
Table 2).
Hospitalization data. PAD patients had a number of
Table 2. Study end points.
Outcome Control Group ðn ¼ 446Þ PAD Group ðn ¼ 223Þ ASA Group ðn ¼ 131Þ TCL Group ðn ¼ 92Þ
Fatal events
Vascular death 50 (0.93)* 38 (1.5)
Myocardial infarction 14 (0.26)* 16 (0.63) 11 (0.74) 5 (0.48)
Ischemic stroke 2 (0.04) 1 (0.04) 0 (0) 1 (0.10)
Haemorrhagic stroke 1 (0.02)* 3 (0.12) 2 (0.13) 1 (0.10)
Other vascular death 33 (0.61) 18 (0.71) 10 (0.67) 8 (0.77)
Non-vascular death 86 (1.60) 63 (2.49) 34 (2.28) 29 (2.79)
Cancer 45 (0.84)* 44 (1.74) 25 (1.68) 19 (1.83)
Other/unknown causes 37/4 (0.76) 14/5 (0.75) 6/3 (0.60) 8/2 (0.96)
Total 136 (2.53)* 101 (3.99) 57 (3.82) 44 (4.23)
Non-fatal vascular events
Myocardial infarction 24 (0.45)* 33 (1.30) 17 (1.14)† 16 (1.54)
Ischemic stroke 5 (0.09)* 8 (0.32) 5 (0.34) 3 (0.29)
Hemorrhagic stroke 1 (0.02)* 2 (0.08) 2 (0.13) 0 (0)
Total 30 (0.56)* 43 (1.70) 24 (1.61)† 19 (1.83)
Major amputation 0 (0.00)* 7 (0.28) 3 (0.20) 4 (0.38)
Data are expressed as number of events/100patients-yr. Provided the low number of unknown causes of death, these have been reported
together with deaths for other causes. PAD Group, peripheral arterial occlusive disease group; ASA Group, patients treated with aspirin;
TCL, patients treated with ticlopidine.
*Indicates the comparison between Control Group and PAD Group; p # 0:05.
†Indicates the comparison between ASA Group and TCL Group; p # 0:05.
Fig. 2. Kaplan–Meier curves for vascular death in controls
(Control Group) and in patients with peripheral arterial
disease (PAD Group). *Log rank test p # 0:05.
Fig. 3. Kaplan–Meier curves for cancer death in controls
(Control Group) and in patients with peripheral arterial
disease (PAD Group). *Log rank test p # 0:05.
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hospital admissions that was double, compared to
controls (median (IQR) 7 (4–12) vs. 3 (0–7), p , 0:05)
while the duration of each single hospital admission
was not different. Only six patients in PAD Group had
never been hospitalized during the observation
period, while the corresponding figure in control
Group was 112, i.e. more than 25%. In total, each
patient had spent 86 days (38–151) in the hospital
while controls 47 days (20–96).
Discussion
PAD still represents a serious medical problem: while
its prevalence parallels the increased survival of
western populations, studies providing level 1–2
evidence on its management are really few. In order
to improve the poor prognosis of PAD patients, the
Consensus Conference3 and other authors8 rec-
ommend treating cardiovascular risk factors, together
with use of antiplatelet agents. Although the report of
ATT9 has not provided conclusive evidence on the
benefits of antiplatelet agents in PAD patients, on the
recent review from Regensteiner and Hiatt has pointed
out that antiplatelet agents are the most effective
treatment for reduction of vascular events in patients
with PAD.10 This is a very widespread practice and has
probably changed the natural history of the disease.
Here we report data on PAD patients prognosis and
survival that can depict a new natural history of the
disease.
In our study, patients with PAD have around four
deaths every 100 patients per year, compared to 2.5 of
the control population; such difference is due to cancer
mortality (þ108%), more than to the cardiovascular
death rate (þ61%), though still elevated. These data
are more noteworthy considering that mortality
reported by consensus document is 7.06 deaths every
100 patients per year and that their vast majority (5.41,
100 patient-yr) were due to vascular death. In our
cohort, cancer represents the first cause of death and
accounts for around 50% of all deaths. Many reasons
could explain such incidence, the most likely is that
mortality for cancer11 has emerged after the reduction
of cardiovascular mortality due to the improvement,
in the last decades, of the management of acute
vascular events. Cancer mortality is higher in our
cohort than in control population, such pattern is
probably due to the higher prevalence of smoking
habit among PAD patients than in the control group.
Lung cancer represents more than 50% of the deaths
for cancer and accounts for half of the excess of cancer
mortality observed in PAD. The remaining excess of
deaths for cancer has been attributed to stomach and
colon localization. Stomach cancer has been recently
associated to smoking habit,12 and the high prevalence
of smokers in our patients might account for such
difference. What remains unexplained is the reason
why only patients assuming aspirin developed this
disease. This is puzzling, provided that previous
studies showed a reduction of the risk of gastric
cancer in patients taking aspirin.13,14 Majority of these
studies, however, were case–control and cross sec-
tional, considering only the use of aspirin in patients
with gastric cancer and controls. The high number of
patients studied was balanced, many times, by a poor
assessment of the time of exposure to aspirin and
many studies did not take into account other con-
ditions. To our knowledge there are no reports on
gastric cancer incidence in patients taking aspirin for a
median time of 13 years. We can hypothesize an
interaction between smoke and aspirin to induce
transformation. An experimental model of gastric
carcinogenesis induced by a guanidine derivate
(MNNG) has demonstrated that aspirin can work as
enhancer of the transformation.15,16
Colon cancer is the other main cause of death for
cancer in PAD patients. Relationship with smoking
habit, and indirectly with PAD, is more vague:
cigarette smoking has been associated inconsistently
with colon cancer, and effect of smoking might be
mediated by DNA microsatellite instability.17,18 Here
too, antiplatelet therapy is associated to a different
prevalence: strongly increased among patients assum-
ing ticlopidine and virtually absent in those assuming
aspirin. The latter data is in good agreement with
previous studies19 demonstrating a protective effect of
aspirin on colon cancer. The prospective relevance of
the association of ticlopidine use with the develop-
ment of colon cancer is reduced by the introduction of
clopidogrel, a new tienopyridine compound more
effective of aspirin and with less side effects of
ticlopidine.20
This is the first time that, in a prospective study,
cancer and not acute vascular events is the main cause
of death in PAD patients. Majority of the cancers are
known to be induced by smoking and, therefore,
tightly associated to PAD. Conditions of observation
closer to real life allowed ascertaining such evidence,
the most important being the long follow-up and the
improved survival of patients. In particular, the
difference in cancer death between patients and
controls was not evident before 5 years of observation
and a different, worse, trend can be observed in PAD
patients after the 5th year of observation. Future
studies aiming to improve quality of life of PAD
patients should also assess this type of end-point.
An excess of non-fatal events can be observed in
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patients, compared to controls. This clinical outcome
does not seem to be reduced over time, when
compared to historical previous studies (1.18–2.35,
100 patient-yr). Since effective treatment of acute
vascular events has reduced vascular mortality it is
likely that this discrepancy is due to the lowered ratio
between fatal and non-fatal events in PAD patients.
Hunink et al have studied the decline in cardiovas-
cular mortality observed from 1980 to 1990 in general
population and established that such decline is largely
due to the reduction of mortality in patients with
cardiovascular disease.4 Similar results have been
obtained by Capewell et al in a longer observation
time, from 1975 to 1994.5 Among the non-fatal events,
amputation is particularly negative for quality of life
of the patients, especially diabetics. Our data on
amputation is lower than that of the consensus (0.47,
100 patient-yr) and might be judged positively;
nevertheless it has to be reminded that no drugs, not
even an aggressive therapeutic approach in type 2
diabetes, like in UKPDS, have been demonstrated to
prevent or reduce lower limb amputation.21
An important concern raises from this study
about the quality of life and the burden on the
health system of these patients: not only their life
expectancy is shorter than that of the general
population, but also the number of hospital admis-
sion and the days spent in hospital is doubled. The
final picture is that the reported gain in survival is
associated to increased need of medical assistance.
The absence of patients not treated with antiplatelet
agents represents a limitation of this study. These
would have provided a more careful verification of the
survival and allowed to establish the net effect of the
treatment provided. At the beginning of the study,
however, evidence of some trials22 – 24 suggested as
useful this treatment, especially in front of the limited
side effects. Moreover, the development of an acute
vascular event, would have required the subsequent
mandatory use of antiplatelet agents. The setting of the
study also could be considered as a limitation,
however, some of the current evidences would have
been impossible to obtain with a randomized con-
trolled trial (RCT). In fact, due to the high cost and
need to keep the patient and observers blinded of the
treatment, RCTs encompass just a small part of the
lifespan of PAD patients: very little was known on
the impact of antiplatelet drugs and on the general
survival of these patients beyond the 5th year of
observation. Another reason of concern is that ran-
domization of treatment is ethically justified in RCT
but in clinical practice the assignment of a therapy is
never left to chance.
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